Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248972 | 0.87 | PARP10 (0.43) | SLC6A4SLC6A2SLC6A3KMT2AMEN1 | |
| SCHEMBL1245817 | 0.85 | AKR1C3 (0.40) | RIPK1AKR1C3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1245722 | 0.78 | HTR1A (0.44) | SLC6A4SLC6A2KMT2AMEN1 | |
| SCHEMBL1246023 | 0.76 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2HRH3 | |
| SCHEMBL1247229 | 0.76 | KDM4E (0.50) | DRD2KMT2AMEN1 | |
| SCHEMBL1247157 | 0.75 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1247033 | 0.74 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1247111 | 0.74 | KCNH2 (0.42) | SLC6A4SLC6A2SLC6A3DRD2KMT2A | |
| SCHEMBL1248229 | 0.74 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1246507 | 0.73 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904069-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9403776-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140296514-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2014-10-02 | — | — | US | disclosed |
| US-8791101-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-7956050-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110046114-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20090118260-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | AMR TECHNOLOGY, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | OPRL1, HTR1B, HTR3C | RIPK1 3687/4885AKR1C3 886/4885SLC6A4 72/4885 |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | OPRD1, OPRK1, OPRL1 | RIPK1 3105/4885AKR1C3 839/4885SLC6A4 136/4885 |
| US-20140296514-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, ADRA2C, HTR2B | RIPK1 4593/4885AKR1C3 666/4885SLC6A4 27/4885 |
| US-20110046114-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, ADRA2C, HTR2B | RIPK1 4593/4885AKR1C3 666/4885SLC6A4 27/4885 |
| US-20090118260-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, ADRA2C, HTR2B | RIPK1 4593/4885AKR1C3 666/4885SLC6A4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.